Navigation Links
Reports in Biological Technology

SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results

BOTHELL, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD ) today reported financial results for the three and six months ended June 30, 2009. Dr. Bruce Morra, SCOLR Pharma's President and CEO, said, "We continue to advance discussions with a number o...

Novavax Reports Second Quarter 2009 Financial Results

ROCKVILLE, Md., Aug. 7 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) today reported a net loss of $8.5 million, or $0.10 per share, for the second quarter of 2009 compared to a net loss of $9.4 million, or $0.15 per share, for the second quarter of 2008. For the six month...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

CORAL GABLES, Fla., Aug. 7 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today reported financial results for the second quarter and six months ended June 30, 2009. Second Quarter 2009 Results For the quarter ended June 30, 2009, th...

NeurogesX Reports Second Quarter 2009 Results

SAN MATEO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- 2Q09 Corporate Highlights: Granted European Commission (EC) approval of Qutenza for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medic...

American Oriental Bioengineering Reports Second Quarter 2009 Financial Results

NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- --2Q09 Revenue Increased 20.7% YoY to $71.2 Million-- --2Q09 Net Income Attributable to Controlling Interest was $13.2 million or $0.17 per Diluted Share-- -- Company Generates Approximately $...

AutoImmune Inc. Reports 2009 Second Quarter Financial Results

PASADENA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, 2009, compared with a net loss of $86,000, or $0.01 per share basic and diluted, for th...

Synthetech Reports First Quarter Fiscal 2010 Results

ALBANY, Ore., Aug. 6 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) today announced financial results for the first quarter of fiscal 2010, which ended June 30, 2009. Revenue for the quarter was $4.7 million, a 5% decrease compared to revenue of $4.9 million in th...

GenVec Reports Second Quarter 2009 Financial Results

GAITHERSBURG, Md., Aug. 6 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today announced its financial results for the second quarter ended June 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) GenVec reported a net loss of $4.8 milli...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced results from operations for the second quarter and six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per shar...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM ), today reported its financial results for the quarter ended June 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) Second Quarter Results Total revenue fo...

OncoGenex Reports Second Quarter 2009 Financial Results

Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI ) today reported unaudited financial results for the second quarter and six mo...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) today reported results for the first quarter fiscal year 2010, ended June 30, 2009. Total revenue for the quarter was $5,061,000 compared to total revenue of $13,660,000 for the first quarter of fiscal ye...

PDI Reports 2009 Second Quarter Financial Results

SADDLE RIVER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- PDI, Inc. (Nasdaq: PDII ), a leading provider of sales and marketing support to U.S. pharmaceutical companies, today reported financial and operational results for the second quarter ended June 30, 2009. Recent highligh...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial resul...

Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today reported financial results for the second quarter ended June 30, 2009. Optimer reported a net loss for the second quarter of 2009 of $12.4 million, or $0.37 per share, which was in lin...

NxStage Reports Second Quarter 2009 Financial Results

LAWRENCE, Mass., Aug. 5 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced net revenue for the second quarter of 2009 of $36.4 million, an increase of 15 percent when compared with revenue of $31.6 mi...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive res...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the second quarter ended June 30, 2009, and provided a corporate update. "Duri...

CuraGen Reports Second Quarter 2009 Financial Results

BRANFORD, Conn., July 31 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) today reported its financial results for the second quarter of 2009 and announced that it had further reduced its outstanding convertible debt and reached an agreement in principle, expr...

ERT Reports Second Quarter 2009 Results

PHILADELPHIA, July 30 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), a leading provider of centralized ECG, ePRO, and other services to the biopharmaceutical, medical device and related industries, announced today results for the second quarter and six-month per...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its financial results and program highligh...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

CHADDS FORD, Pa., July 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) today reported financial results for the second quarter of 2009, including a full quarter of results of Indevus Pharmaceuticals, Inc., which Endo acquired during the first quarter. Tota...

Caliper Life Sciences Reports Second Quarter 2009 Results

HOPKINTON, Mass., July 30 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP ) today reported that for the second quarter of 2009 revenues were $32.1 million compared to $34.0 million for the second quarter of 2008. Divestitures and foreign currency translation negati...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL ) today announced its financial results for the three and six months ended June 30, 2009. Financial Highlights Adjusted diluted EPS, which excludes the impact of certain purchase acc...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

RICHMOND, Calif., July 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today reported second quarter 2009 financial results and accomplishments. For the second quarter ended June 30, 2009, Sangamo reported a consolidated net loss of $4.5 million, or $0.11...

Neurocrine Biosciences Reports Second Quarter 2009 Results

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced its financial results for the quarter ended June 30, 2009. For the second quarter of 2009, the Company reported a net loss of $15.3 million, or $0.39 per share, compared with ...

Sunesis Reports Financial Results for the Second Quarter 2009

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today reported financial results for the second quarter ended June 30, 2009. Total revenue for the second quarter of 2009 was $3.5 million, with a net loss of $22.9 ...

Cynosure Reports Second Quarter 2009 Financial Results

WESTFORD, Mass., July 28 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO ), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced financial results for the three months ended June 30, 2009. Second...

NeoGenomics Reports Second Quarter 2009 Results

FT. MYERS, Fla., July 28 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM ), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2009. Highlights: Revenue increased 53% versus Q2 ...

Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.

ST. LOUIS, July 23 /PRNewswire-FirstCall/ --Sigma-Aldrich Corporation (Nasdaq: SIAL ), a leading Life Science and High Technology company, reported second quarter 2009 diluted EPS of $0.68 compared to $0.70 in the second quarter of 2008. For the six months ended June 30, 2009, reporte...

Neogen Reports 16% Increase in Revenues

LANSING, Mich., July 21 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG ) today announced a 16% increase in revenues for its 2009 fiscal year, which ended May 31, and a continuation of the company's outstanding record of profitability. Neogen's revenues for FY 2009...

Schering-Plough Reports Financial Results for 2009 Second Quarter

KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported financial results for the 2009 second quarter. "Our successful diversification strategy and strong execution by our people have given us the strength to again...

Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic pati...

Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and si...

China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results

SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT ) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for t...

Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males

PHOENIX, July 2 /PRNewswire/ -- As many as five to ten million males in the U.S. struggle quietly with an eating disorder because they're ashamed to admit they have the illness, reports Remuda Ranch Programs for Eating and Anxiety Disorders . Healthcare professionals, family members and close...

Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer

- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit - GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported that the St. Galle...

Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16%

STATESVILLE, N.C., June 24 /PRNewswire-FirstCall/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU ) today reported record sales, earnings, and order backlog for its fiscal year ended April 30, 2009. Net earnings for the year increased 36% to $4,247,000, or $1.66 per diluted share, up from...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its li...

BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device

LAVAL, QC, June 17 /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a biotechnology company developing biotherapeutic thermogels for regenerative medicine, today announced statistically significant results from an analysis of patients who completed their 12 month follow-up in the BST-CarGel(R...
Other Tags
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today ... differences in genetic ancestry of individuals from across ... immigrants first arrived more than four hundred years ago, ... as a meeting place for peoples from different continents. ... mixing of peoples with African, European, and American origins ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
(Date:12/19/2014)... All children should have their eyesight checked between the ... experts say. The new vision-screening guidelines for preschool-aged ... National Center for Children,s Vision Health. The panel ... for eye problems, particularly vision issues that require ... strabismus (a disorder of eye alignment). Early detection ...
(Date:12/19/2014)... Dense bunches of bacteria called biofilms can be found on ... The researchers said these biofilms were especially prevalent on ... these biofilms may represent an increased likelihood of colon cancer ... risk for the disease, the researchers said. Like tooth ... the mucus layer of cells lining the colon, according to ...
(Date:12/19/2014)... NC (PRWEB) December 19, 2014 Surviving Mesothelioma ... and EPA information indicates that these pipes can leach asbestos ... go to the full story on the Surviving Mesothelioma ... the erosion of natural asbestos deposits, decaying water mains made ... drinking water. , To protect consumers from mesothelioma ...
(Date:12/19/2014)... Kan. (PRWEB) December 19, 2014 B. ... exclusively to healthcare providers, has been retained to lead ... Estes Park Medical Center in Estes Park, Colo. The ... E. Smith has recently placed more than 900 healthcare ... (EPMC) is a 25-bed, not-for-profit critical access hospital and ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Novellus ... Patient Care: Pharmacy & Clinics™, an independent journal ... team treating and caring for patients inside the ... care expands to provide optimal access to quality ... a forum for the team treating and coordinating ...
Breaking Medicine News(10 mins):Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Could Bacteria Play a Role in Colon Cancer? 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3
Other Contents